Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunology
Researchers from Technical University of Munich, Department of Hematology-Oncology publish findings in cancer vaccines immunology
July 16th, 2008
Scientists discuss in 'ctls Directed against HER2 specifically cross-react with HER3 and HER4' new findings in cancer vaccines. According to recent research from Munich, Germany, "The human epidermal growth factor receptor 2 (HER2) has been targeted as a breast cancer-associated Ag by T cell-based immunotherapeutical strategies such as cancer vaccines and adoptive T cell transfer. The prerequisite for a successful T cell-based therapy is the induction of T cells capable of recognizing the HER2-expressing tumor cells." "In this study, we generated human cytotoxic T cell clones directed against the HER2(369-377) epitope known to be naturally presented with HLA-A*0201....
Source: Vaccine Weekly (2008-07-16)
|
